Efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis: A prospective and randomized clinical study

Hui-Juan Shi, Hongbin Song, Qian-Ying Zhao, Chun-Xia Tao, Min Liu, Qin-Qin Zhu, Hui-Juan Shi, Hongbin Song, Qian-Ying Zhao, Chun-Xia Tao, Min Liu, Qin-Qin Zhu

Abstract

Background: We evaluated the efficacy and safety of combined high-dose interferon (IFN) and red light therapy for the treatment of subclinical and latent human papillomavirus (HPV) infections.

Methods: Ninety women diagnosed with subclinical or latent HPV infection were randomized to receive topical application of low-dose recombinant IFNα-2b (1 million IU), high-dose IFNα-2b (9 million IU), or a combination of high-dose IFNα-2b and red light therapy on the cervix and vagina. All patients received treatment once daily for 4 weeks. HPV titer was measured immediately and 4, 8, and 12 weeks after treatment to determine the rates of viral clearance and infection cure. Treatment of HPV-associated vaginitis and cervicitis was also evaluated.

Results: Results showed that immediately and 4, 8, and 12 weeks after treatment, the HPV clearance rates and infection cure rates were higher in the high-dose IFN and combination groups compared to the low-dose IFN group. High-dose IFN and combination therapies were significantly effective against both low-risk and high-risk HPV infections. Although the cure rates for vaginitis and cervicitis were significantly higher in the high- compared to the low-dose IFN group, rates were even higher in the combination group compared to the high-dose IFN group. Mild adverse effects were reported by a very small subset of patients (3/30) in the combination group.

Conclusions: This study suggests that combination of high-dose IFN and red light therapy is safe and effective against subclinical and latent HPV infections.

Conflict of interest statement

The authors have no conflicts of interest relevant to this article.

Figures

Figure 1
Figure 1
A, HPV clearance rates. B, Cure rates for subclinical and latent infections. C, Cure rates for HPV-associated vaginitis and cervicitis. ∗P < .0125 vs low-dose IFN group; #P < .0125 vs high-dose IFN group. HPV = human papillomavirus, IFN = interferon,

References

    1. Hoffmann M, Klose N, Gottschlich S, et al. Detection of human papillomavirus DNA in benign and malignant sinonasal neoplasms. Cancer Lett 2006;239:64–70.
    1. Kumar B, Gupta S. The acetowhite test in genital human papillomavirus infection in men: what does it add? J Eur Acad Dermatol Venereol 2001;15:27–9.
    1. Schiffman M, Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev 2013;22:553–60.
    1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12–9.
    1. Moscicki AB. Impact of HPV infection in adolescent populations. J Adolesc Health 2005;37(6 suppl):S3–9.
    1. Shen XH, Liu SH. Human papillomavirus genotypes associated with mucopurulent cervicitis and cervical cancer in Hangzhou, China. Asian Pac J Cancer Prev 2013;14:3603–6.
    1. Srivastava S, Shahi UP, Dibya A, et al. Distribution of HPV genotypes and involvement of risk factors in cervical lesions and invasive cervical cancer: a study in an Indian population. Int J Mol Cell Med 2014;3:61–73.
    1. Mirzaie-Kashani E, Bouzari M, Talebi A, et al. Detection of human papillomavirus in chronic cervicitis, cervical adenocarcinoma, intraepithelial neoplasia and squamus cell carcinoma. Jundishapur J Microbiol 2014;7:e9930.
    1. Guo YL, You K, Qiao J, et al. Bacterial vaginosis is conducive to the persistence of HPV infection. Int J STD AIDS 2012;23:581–4.
    1. Zaak D, Hofstetter A, Frimberger D, et al. Recurrence of condylomata acuminata of the urethra after conventional and fluorescence-controlled Nd:YAG laser treatment. Urology 2003;61:1011–5.
    1. Blume JE, Oseroff AR. Aminolevulinic acid photodynamic therapy for skin cancers. Dermatol Clin 2007;25:5–14.
    1. Zhang Z, Lu XN, Liang J, et al. Evaluation of photodynamic therapy using topical aminolevulinic acid hydrochloride in the treatment of condylomata acuminate. Int J Clin Exp Med 2015;8:6517–21.
    1. Wang HW, Zhang LL, Miao F, et al. Treatment of HPV infection-associated cervical condylomata acuminata with 5-aminolevulinic acid-mediated photodynamic therapy. Photochem Photobiol 2012;88:565–9.
    1. Shi H, Zhang X, Ma C, et al. Clinical analysis of five methods used to treat condylomata acuminata. Dermatology 2013;227:338–45.
    1. Terenzi F, Saikia P, Sen GC. Interferon-inducible protein, P56, inhibits HPV DNA replication by binding to the viral protein E1. EMBO J 2008;27:3311–21.
    1. Rockley PF, Tyring SK. Interferons alpha, beta and gamma therapy of anogenital human papillomavirus infections. Pharmacol Ther 1995;65:265–87.
    1. Eron LJ, Judson F, Tucker S, et al. Interferon therapy for condylomata acuminata. N Engl J Med 1986;315:1059–64.
    1. Friedman-Kien AE, Eron LJ, Conant M, et al. Natural interferon alfa for treatment of condylomata acuminata. JAMA 1988;259:533–8.
    1. Koromilas AE, Li S, Matlashewski G. Control of interferon signaling in human papillomavirus infection. Cytokine Growth Factor Rev 2001;12:157–70.
    1. Chang YE, Pena L, Sen GC, et al. Long-term effect of interferon on keratinocytes that maintain human papillomavirus type 31. J Virol 2002;76:8864–74.
    1. Song E, Reja D, Silverberg N, et al. Phototherapy: kids are not just little people. Clin Dermatol 2015;33:672–80.
    1. Niu T, Tian Y, Ren Q, et al. Red light interferes in UVA-induced photoaging of human skin fibroblast cells. Photochem Photobiol 2014;90:1349–58.
    1. Holder MJ, Milward MR, Palin WM, et al. Effects of red light-emitting diode irradiation on dental pulp cells. J Dent Res 2012;91:961–6.
    1. Reddy GK, Stehno-Bittel L, Enwemeka CS. Laser photostimulation accelerates wound healing in diabetic rats. Wound Repair Regen 2001;9:248–55.
    1. Odom RB, James WD, Berger TG (ed.) Viral diseases. In: Andrews’ Diseases of the Skin Clinical Dermatology. 9th ed. Science Press, Harcourt Asia W.B. SAUNDERS; 2001:509–520.
    1. Amsel R, Totten PA, Spiegel CA, et al. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983;74:14–22.
    1. Workowski KA, Bolan GA. Centers for Disease Control and Prevention: sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015;64:1–37.
    1. Strand A, Rylander E. Human papillomavirus. Subclinical and atypical manifestations. Dermatol Clin 1998;16:817–22.
    1. Arbyn M, Castellsagué X, De Sanjosé S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675–86.
    1. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003;16:1–7.
    1. Muñoz N, Bosch FX, de Sanjosé S, et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518–27.
    1. Chao A, Huang HJ, Lai CH. Human papillomavirus research on the prevention, diagnosis, and prognosis of cervical cancer in Taiwan. Chang Gung Med J 2012;35:297–308.
    1. Coutlée F, Ratnam S, Ramanakumar AV, et al. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. J Med Virol 2011;83:1034–41.
    1. Lin H, Ma YY, Moh JS, et al. High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan. Gynecol Oncol 2006;101:40–5.
    1. Wang HW, Wang XL, Zhang LL, et al. Aminolevulinic acid (ALA)-assisted photodynamic diagnosis of subclinical and latent HPV infection of external genital region. Photodiagnosis Photodyn Ther 2008;5:251–5.
    1. Clifford GM, Gallus S, Herrero R, et al. IARC HPV Prevalence Surveys Study Group: worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005;366:991–8.
    1. De Sanjosé S, Diaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453–9.
    1. Cho HW, So KA, Lee JK, et al. Type-specific persistence or regression of human papillomavirus genotypes in women with cervical intraepithelial neoplasia 1: a prospective cohort study. Obstet Gynecol Sci 2015;58:40–5.
    1. Massad LS, Einstein MH, Huh WK, et al. 2012 ASCCP Consensus Guidelines Conference: 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2013;17(5 suppl 1):S1–27.
    1. Rodríguez AC, Schiffman M, Herrero R, et al. Proyecto Epidemiológico Guanacaste Group: rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008;100:513–7.
    1. Baron S, Tyring SK, Fleischmann WR, Jr, et al. The interferons. Mechanisms of action and clinical applications. JAMA 1991;266:1375–83.
    1. Varela M, Diaz-Rosales P, Pereiro P, et al. Interferon-induced genes of the expanded IFIT family show conserved antiviral activities in non-mammalian species. PLoS One 2014;9:e100015.
    1. Levine LA, Elterman L, Rukstalis DB. Treatment of subclinical intraurethral human papilloma virus infection with interferon alfa-2b. Urology 1996;47:553–7.
    1. De Palo G, Stefanon B, Rilke F, et al. Human fibroblast interferon in cervical and vulvar intraepithelial neoplasia associated with viral cytopathic effects. A pilot study. J Reprod Med 1985;30:404–8.
    1. Frost L, Skajaa K, Hvidman LE, et al. No effect of intralesional injection of interferon on moderate cervical intraepithelial neoplasia. Br J Obstet Gynaecol 1990;97:626–30.
    1. Cong X, Sun R, Zhang X, et al. Correlation of human papillomavirus types with clinical features of patients with condyloma acuminatum in China. Int J Dermatol 2016;55:775–80.
    1. Yu W, Naim JO, Lanzafame RJ. Effects of photostimulation on wound healing in diabetic mice. Lasers Surg Med 1997;20:56–63.
    1. Yu W, Naim JO, Lanzafame RJ. The effect of laser irradiation on the release of bFGF from 3T3 fibroblasts. Photochem Photobiol 1994;59:167–70.
    1. Senba M, Buziba N, Mori N, et al. Human papillomavirus infection induces NF-κB activation in cervical cancer: a comparison with penile cancer. Oncol Lett 2011;2:65–8.
    1. Gillet E, Meys JF, Verstraelen H, et al. Bacterial vaginosis is associated with uterine cervical human papillomavirus infection: a meta-analysis. BMC Infect Dis 2011;11:10.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever